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transplant in myeloma patients treated with this regimen, but
without Xcellerated T Cells. The T cell receptor repertoire of
leukapheresis samples as measured by V	 spectratyping demon-
strates marked skewing. Following the Xcellerate Process, the
repertoire returns to a more normal pattern (n  5; p  0.01). In
addition, the T cell repertoire measured 25 days following T cell
infusion (Day 28 posttransplant) demonstrates a more normal
pattern than prior to T cell infusion (n  5). This is in marked
contrast to the severe skewing of T cell receptor diversity normally
seen in myeloma patients following autologous stem cell transplan-
tation (Mariani et al, BJH 2001). Data on clinical outcomes will be
presented.
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LONG TERM OUTCOME FOLLOWING AUTOLOGOUS AND ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR
LYMPHOMA
Deshpande, A.T., Bociek, G.R., Bierman, P.J., Vose, J.M., Lynch, J.C.,
Armitage, J.O. University of Nebraska Medical center, Omaha, NE
Follicular lymphoma (FL) accounts for approximately 25-35% of
all cases of non-Hodgkin’s Lymphoma (NHL). Autologous
(ASCT) and allogeneic (alloSCT) hematopoietic stem cell trans-
plantation can induce prolonged remissions in patients with FL,
and studies of alloSCT demonstrate very low relapse rates and
evidence of a plateau on event-free survival (EFS) curves, suggest-
ing the possibility that some patients may be cured with this
modality. We present the long-term outcome in 204 patients with
FL treated with ASCT (n  186) or alloSCT (n  18) between
04/83 and 05/98. For ASCT and alloSCT groups respectively the
median age was 45 vs. 39 years and the median time from diagnosis
to transplant 27 vs 24 months. The majority of patients in both
groups had follicular grade 2 histology, and the conditioning reg-
imen was cyclophosphamide/total body irradiation (Cy/TBI) in
54% of ASCT and 72% of alloSCT. The median follow-up of
surviving patients is 7.8 years (range 1.7 to 19.2 years). Patients
who received an alloSCT had a superior ﬁve-year EFS (76% vs.
41%; p  0.034), but not overall survival (OS) (76% vs. 61%; p 
0.18). To control for the possible confounding effect of preparative
regimen we performed a limited analysis of all patients undergoing
transplantation with Cy/TBI, and found that patients undergoing
alloSCT had superior EFS (p  0.034) and a trend toward im-
proved OS (p  0.18) compared with ASCT. Multivariate analysis
of patients undergoing ASCT demonstrated an inferior EFS in
patients who received 3 prior chemotherapies (hazard ratio [HR]
 3.5; 95% conﬁdence interval [CI]  1.8-7.0, p  0.001) and in
patients 60 years of age (HR  4.7; 95% CI  1.6-13.8, p 
0.001). Variables predicting for an increased risk of death in ASCT
included3 prior chemotherapies (HR 5.0; 95% CI 2.4-10.6,
p 0.0001), age60 years (HR 9.2; 95% CI 2.8-30, p 0.001),
female gender (HR  2.4; 95% CI  1.2-4.9, p  0.013), and the
presence of resistant disease (HR  4.9; 95% CI  1.8-13.6, p 
0.01). In conclusion, this data offers some evidence that with
adequate follow-up alloSCT leads to superior EFS compared with
ASCT, but because of morbidity/mortality associated with al-
loSCT OS is similar in both groups. Notwithstanding issues of
selection bias, the observation that these differences are not ac-
counted for by the intensity of the preparative regimen suggests
that a lack of tumor contamination, an allogeneic graft-versus-
lymphoma effect, or both may be responsible for the improved
outcome.
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THE CITY OF HOPE EXPERIENCE WITH NOVEL TRANSPLANT REGI-
MENS THAT INCORPORATE STANDARD AND ESCALATED DOSE 90YT-
TRIUM IBRITUMOMAB TIUXETAN (90Y-ZEVALIN) RADIOIMMUNO-
THERAPY (RIT) FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT) IN PATIENTS WITH B-CELL NON-HODGKIN’S LYMPHOMA
(NHL): TARGETED INTENSIFICATION WITHOUT INCREASED TOXICITY
AND ELIMINATION OF TOTAL BODY IRRADIATION (TBI)
Nademanee, A.1, Fung, H.1, Molina, A.2, Krishnan, A.1, Rodriguez,
R.1, Popplewell, L.1, Spielberger, R.T.1, O’Donnell, M.1, Snyder, D.1,
Parker, P.1, Stein, A.1, Kogut, N.1, Falk, P.1, Sahebi, F.1, Zain, J.1,
Saville, W.2, Raubitschek, A.1, Forman, S.J.1 1. City of Hope Cancer
Center (COH), Duarte, CA; 2. IDEC Pharmaceuticals Corporation,
San Diego, CA
Background: 90Y-Zevalin was the 1st FDA-approved RIT for
treatment of pts with relapsed or refractory CD20 low-grade,
follicular, or transformed B-cell NHL, including rituximab-refrac-
tory NHL. Two COH clinical trials are currently investigating
whether standard (0.4 mCi/kg) or escalated doses of 90Y-Zevalin
can be combined safely with myeloablative regimens for ASCT.
Methods/Results: 1) A dose escalation study of 90Y-Zevalin with
dosimetric guidance (maximum radiation dose to the liver of 1000
cGy)  high-dose VP-16  cyclophosphamide (CY) has accrued
26 pts who are evaluable for efﬁcacy and safety. Median age was 49
(25-58). Median dose of 90Y-Zevalin delivered was 71 mCi (37-105
mCi). All pts with measurable disease achieved remission, except
one pt had a positive PET scan. 4 pts received IF-XRT to sites of
prior bulky disease. Median day to ANC 1,000 was 10 days
(8-17). Median days to platelet count 50, 000 was 20 (12-123).
With a median follow-up of 20 months (range 1-40), 21 pts (81%)
are alive and in remission. 2) The standard-dose study of 90Y-
Zevalin (0.4 mCi/kg)  high-dose BEAM has accrued 12 pts,
primarily over the age of 60. Dosimetry was not performed. Me-
dian age was 61 (56-78). All pts engrafted promptly after ASCT
and there were no transplant-related deaths. The median total dose
of 90Y-Zevalin was 32 mCi (range: 20.7-40). Because stem cell
support was used, a maximum 40 mCi dose of Zevalin was allowed.
With a median follow-up of 9 months (range, 4-16), 2 pts have
relapsed, and one of these died from progressive disease. The
remaining 10 pts (83%) are well without evidence of NHL. Con-
clusions: Results from the dose escalation study suggest that high-
dose 90Y-Zevalin can be safely administered with high-dose VP-
16/CY; that high-dose 90Y-Zevalin can be used in place of TBI
without the need for a lead-shielded isolation room; and that this
new high-dose combination is effective in heavily pre-treated pts
with poor-risk NHL. Results from the second study indicate that
the combination of conventional-dose 90Y-Zevalin  high-dose
BEAM is a well-tolerated and easily administrated ASCT regimen
for older pts with aggressive CD20 NHL and does not require
dosimetry. These preliminary results taken in aggregate suggest
that incorporation of 90Y-Zevalin into novel SCT regimens pro-
vides a targeted intensiﬁcation of the transplant regimen and po-
tentially increased anti-tumor activity without added toxicity.
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ZEVALIN DOSE-ESCALATION FOLLOWED BY HIGH-DOSE BEAM AND
AUTOTRANSPLANT IN CD20 RELAPSED OR REFRACTORY NON-
HODGKIN LYMPHOMA (NHL)
Winter, J.N.1, Inwards, D.2, Erwin, W.3, Wiseman, G.2, Rademaker,
A.1, Patton, D.R.1, Williams, S.1, Tallman, M.S.1, Mehta, J.1, Sin-
ghal, S.1, Micallef, I.2, Multani, P.4, Zimmer, M.1, Spies, S.1, Molina,
A.4, White, C.4, Gordon, L.I.1 1. Feinberg School of Medicine, North-
western University, Chicago, IL; 2. Mayo Clinic College of Medicine,
Rochester, MN; 3. MD Anderson Cancer Center, Houston, TX; 4.
IDEC Pharmaceuticals, San Diego, CA
90Y Zevalin was added to high-dose BEAM followed by auto-
transplant in 22 patients with relapsed or refractory CD20 NHL
with the goal of increasing progression-free and overall survival
(PFS, OS). Cohorts of 3-6 patients were treated at doses calculated
to result in increasing radiation exposure(100, 300, 500, 700 cGy)
to the critical organ (liver, lung or kidney). On D -22, rituximab(R)
250 mg/m2 was administered followed by the imaging dose of 111In
Zevalin (5 mCi). Imaging was performed immediately and at 4, 24,
72, and 144 hours post-injection; dosimetry was performed on D
-15. On D -14, R at 250 mg/m2 was administered followed by 90Y
Zevalin at a dose calculated to deliver the cohort-prescribed ab-
sorbed radiation dose to the critical organ. On D -6 through -1,
patients received BEAM. On D 0, a minimum of 2.0  106
CD34 cells/kg was infused and G-CSF 5 g/kg SQ daily was
begun. The median age was 53 (range: 25-72). 5 patients had
mantle cell lymphoma, 9 had diffuse aggressive NHL, 4 had low
grade NHL, and 4 had transformed NHL. The majority (55%)
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had received 3 or more treatment regimens. Prior therapy included
R in half of all patients. 12 patients had never achieved a complete
remission, and 8 had primary refractory disease. Toxicity was
similar to that reported with BEAM alone and included a fall in
DLCO for most patients with 1 patient experiencing a transient
decline to below 50% of the predicted values corrected for hemo-
globin. Grade III/IV toxicities included infection, fever, stomatitis,
nausea, vomiting, diarrhea, hemorrhage, and edema. One patient
at the 700 cGy level developed veno-occlusive disease which con-
stituted a dose-limiting toxicity (maximum total bilirubin 10.4),
necessitating the enrollment of 3 additional patients at that dose
level. Ascites resolved by D 34, and total bilirubin was normal by
D 60. At the 700 cGy level, administered radioactivities ranged
from 0.27 to 0.73 mCi/kg (median: 0.37), and the total body dose
from 43 to 12 cGy (median: 99 cGy). In all but one case, the critical
organ was the liver. Engraftment by ABMTR criteria occurred at
a median of 10 days (range: 8-18) for 1000 granulocytes and 21
days (range: 12-40) for platelet recovery to 20,000. With a median
follow-up of 12 months, the OS is 60% at 3 years. PFS is 47% at
both 2 and 3 years. Accrual continues at the 900 cGy dose level
which is anticipated to require greater than the .4 mCi/kg dose of
90 Y Zevalin recommended for conventional treatment.
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A DECADE OF MYELOABLATIVE HLA-MATCHED SIBLING MARROW
TRANSPLANTATION FOR CHILDREN WITH SEVERE SICKLE CELL DIS-
EASE: OUTCOMES AND LESSONS LEARNED FROM THE ATLANTA EX-
PERIENCE
Haight, A.E.1,2, Rudolph, C.A.1, Eckman, J.R.1,3, Hsu, L.L.3,4, Bow-
man, L.C.1,2, Chiang, K.-Y.2, Olson, E.2, Lauer, M.2, Yeager, A.M.5,
Adamkiewicz, T.1, Olson, T.1,2 1. Emory University School of Medicine,
Atlanta, GA; 2. AFLAC Cancer Center and Blood Disorders Service,
Children’s Healthcare of Atlanta, Atlanta, GA; 3. Georgia Comprehen-
sive Sickle Cell Center, Atlanta, GA; 4. Drexel University/Marian
Anderson Sickle Cell Center, Philadelphia, PA; 5. University of Pitts-
burgh School of Medicine, Pittsburgh, PA
Allogeneic BMT offers a cure to select patients with sickle cell
disease (SCD), but the limited available long-term data and con-
cerns about the risk-to-beneﬁt ratio present dilemmas for families
and clinicians. We report favorable outcomes in a large single
institution experience with myeloablative matched sibling BMT
for children with severe SCD between December 1993 and April
2003. Sixteen patients (12 male) with a median age 7.7 years
(3.3-17.1) were transplanted for primary indications of CVA (n 
8), recurrent TIA (n  1), recurrent ACS (n  6), and frequent
VOC pain (n  1). Graft source was HLA-identical sibling mar-
row, with 9 HgbAS donors. Preparative regimen (BU 14 mg/kg,
CTX 200 mg/kg, ATG 90 mg/kg) was well tolerated. Special
measures included aggressive management of hypertension and
hypomagnesemia, maintenance of Hgb 10-12 g/dl and platelets
50k, and prolonged antiepileptics while on CSA for GVHD
prophylaxis. The initial 8 patients were treated on a multicenter
consortium trial (Walters et al). With median follow-up 36 months
(6-84), OS and DFS are 100% and there are no graft failures. Two
patients have stable mixed chimerism (72 and 69% donor) with low
HgbS (0 and 2.5%) and no clinical SCD. Median WBC engraft-
ment was day 12.5 (10-21) and platelet engraftment day 31.5
(17-46). No patients experienced aGVHD. The two oldest patients
had cGVHD related to medication non-compliance. Two of the 8
patients with prior CVA had serious CNS events, including seizure
and hemorrhage on day 0 in a moya-moya patient and late pro-
gressive cerebrovascular disease in a patient with prior CVA. None
had new clinical CVA. One patient (age 16.7 years) without prior
CVA had a seizure attributed to “non-compliance rebound” with
CSA. Infections included two episodes of Zoster, one early mul-
tiorganism bacteremia, and one late pneumococcal bacteremia. All
patients have excellent functional status and attend school/college.
These favorable outcomes have led our center to offer this trans-
plant treatment as a standard-of-care with principles speciﬁc to
SCD: 1)careful psychosocial screening and transplantation at a
young age, 2)supportive measures to avoid CNS events, and 3)
long-term follow-up with attention to infection and cerebrovascu-
lar disease that may relate to SCD rather than the BMT. In our
experience, collaborative management with a comprehensive sickle
cell program optimizes referral of appropriate patients, reduces
peritransplant complications, and optimizes outcomes.
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BONE MARROW TRANSPLANTATION (BMT) FOR CHILDREN AND AD-
OLESCENTS WITH SEVERE ACQUIRED APLASTIC ANEMIA (SAA): A
SINGLE CENTER EXPERIENCE IN 171 PATIENTS (PTS) COMPARING
TWO DIFFERENT PREPARATORY REGIMENS
Bonﬁm, C.M.S., de Medeiros, C.R., Bitencourt, M.A., Moreira, V.,
Setubal, D.C., Neves, H., Lorenzatto, C., Ruiz, J., Zanis-Neto, J.,
Pasquini, R. Federal University of Parana, Curitiba, PR, Brazil
Background: BMT from a histocompatible sibling is the treat-
ment of choice for young pts with SAA. Those who have received
few transfusions can achieve long term survival after conditioning
with Cyclophosphamide 200mg/kg (CY200). For pts heavily trans-
fused, graft failure (GF) after this regimen is high and led to the
addition of Anti-lymphocyte globulin to improve outcome. Unfor-
tunately this drug is not easily available in developing countries and
from 01/03 on, all pts with more than 15 transfusions pre-BMT
were given Busulfan 12mg/kg (BU12) and CY 120mg/kg (CY120).
Material and Methods: Between 10/79 and 09/03,396 pts with
SAA were transplanted at our BMT Unit. In this study we per-
formed a retrospective analysis in 171 pts 21 years, who received
an HLA-identical sibling transplant (bone marrow), and metho-
trexate  cyclosporine as GVHD immuneprophylaxis. All pts
received prophylactic antibiotics according to common practice.
Preparatory regimen: CY200: 92 pts and BU12/CY120: 79 pts.
Median age at transplant: 13yr (range 1 – 20yr). Gender: 64F/
107M. Median disease duration: 3m (range: 0-232m). Median
transfusions pre-BMT: 23UI (range: 0-238). TNC: 1, 48–12, 9 
108/kg (M: 3, 36). Results: 122 pts are alive and well 263-6141
days post-BMT (M: 2664 days). In the CY200 group 40 pts re-
ceived 15 transfusions and 34 were evaluable for engraftment: 2
pts had primary GF and 20 had late GF (Median: 288 days; range:
100-734 days post-BMT). Mucosytis occurred in 9/92pts.
A-GVHD grade III-IV occurred in 3/84 evaluable pts and exten-
sive C-GVHD in 2/78pts. Estimated overall survival in 16 years is
86% for pts15 transfusions and 50% for pts15 transfusions. In
the BU12/CY120 group, 76 pts were evaluable for engraftment, 1
pt had primary GF and 11 had late GF (median: 524 days post-
BMT). Mucosytis grade III-IV occurred in 27 pts. 8/76pts had
A-GVHD grade III-IV and 8/72pts had extensive C-GVHD. Es-
timated overall survival in this group is 70% (P value  0.002).
Forty-nine pts are dead: Bu12/CY120: 22 pts, CY200  15: 20pts
and CY200  15: 7 pts). .Causes of death in both groups were
mainly related to infection. Conclusion: The BU12  CY120
regimen decreased the GF rate and improved overall survival for
pts heavily transfused but it was associated with more toxicity and
higher transplant related mortality.
SOLID TUMORS
62
LESSONS FROM A POSITIVE RANDOMIZED TRIAL OF HIGH-DOSE CHE-
MOTHERAPY IN METASTATIC BREAST CANCER: LEARN FROM OUR
MISTAKES, BUILD ON OUR SUCCESSES, DRAIN THE BATHWATER,
HOLD THE BABY
Crown, J.P.1, Leyvraz, S.2, Verrill, M.3, Guillem, V.4, Efremedis, A.5,
Baselga, J.6, Garcia Conde-Bru, J.7, Welch, R.8, Leonard, R.9 1. St
Vincent’s, Dublin, Ireland; 2. CHUV-, Lausanne, Switzerland; 3. New-
castle General, Newcastle, United Kingdom; 4. Duran y Reynals, Bar-
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